These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 34159077)

  • 1. Intermediate-term results of a prospective, multicenter study on remote programming sacral neuromodulation for refractory overactive bladder.
    Zhang Y; Meng L; Zhang P; Tian X; Chen G; Li Y; Zhang Y; Xu Z; Wei Z; Zhang W; Ma L; Shi B; Liao L; Wang J
    Transl Androl Urol; 2021 May; 10(5):1966-1975. PubMed ID: 34159077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of clinical performance and safety for the rechargeable InterStim Micro device in overactive bladder subjects: 6-month results from the global postmarket ELITE study.
    Goudelocke C; Xavier K; Pecha B; Burgess K; Perrouin-Verbe MA; Krlin R; Michaels J; Shah S; Peyronnet B; Zaslau S; Champs M; Papi B; Bittner K; Elterman D; Nitti V
    Neurourol Urodyn; 2023 Apr; 42(4):761-769. PubMed ID: 36917003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Remotely programmed sacral neuromodulation for the treatment of patients with refractory overactive bladder: a prospective randomized controlled trial evaluating the safety and efficacy of a novel sacral neuromodulation device.
    Zhang Y; Zhang P; Tian X; Chen G; Li Y; Zhang Y; Xu Z; Wei Z; Zhang W; Ma L; Shi B; Liao L; Wang J
    World J Urol; 2019 Nov; 37(11):2481-2492. PubMed ID: 30809700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sacral Neuromodulation Using a Novel Device with a Six-contact-point Electrode for the Treatment of Patients with Refractory Overactive Bladder: A Multicenter, Randomized, Single-blind, Parallel-control Clinical Trial.
    Liao L; Zhou Z; Chen G; Xu Z; Huang B; Chong T; Chen Q; Wei Z; Shen B; Chen Z; Ling Q; Weng Z; Jiang H; Shi B; Li Y; Wang Y
    Eur Urol Focus; 2022 Nov; 8(6):1823-1830. PubMed ID: 35525837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder.
    Noblett K; Siegel S; Mangel J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Bennett J; Zylstra S; Kan F; Berg KC
    Neurourol Urodyn; 2016 Feb; 35(2):246-51. PubMed ID: 25546568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sacral Neuromodulation with the InterStim™ System for Intractable Lower Urinary Tract Dysfunctions (SOUNDS): Results of Clinical Effectiveness, Quality of Life, Patient-Reported Outcomes and Safety in a French Multicenter Observational Study.
    Chartier-Kastler E; Le Normand L; Ruffion A; Dargent F; Braguet R; Saussine C; Tanneau Y; Graziana JP; Ragni E; Rabut B; Rousseau T; Biardeau X; Gamé X; Pierrevelcin J; Brassart E; Fourmarier M; Stoica G; Berrogain N; Yaghi N; Pecoux F; Capon G; Ferchaud J; Peyrat L; Bryckaert PE; Karsenty G; Melotti A; Abouihia A; Keller DUJ; Cornu JN
    Eur Urol Focus; 2021 Nov; 7(6):1430-1437. PubMed ID: 32907782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel leadless, miniature implantable Tibial Nerve Neuromodulation System for the management of overactive bladder complaints.
    Heesakkers JPFA; Digesu GA; van Breda J; Van Kerrebroeck P; Elneil S
    Neurourol Urodyn; 2018 Mar; 37(3):1060-1067. PubMed ID: 28892221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder.
    Siegel S; Noblett K; Mangel J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Bennett J; Zylstra S; Berg KC; Kan F; Irwin CP
    Neurourol Urodyn; 2015 Mar; 34(3):224-30. PubMed ID: 24415559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sacral neuromodulation for overactive bladder using the InterStim and BetterStim systems.
    Meng L; Tian Z; Zhang Y; Wang J; Liao L; Chen G; Tian X; Ma L; Li Y; Shi B; Zhang Y; Ling Q; Zhang P; Wei Z; Zhong T; Xu Z; Li J; Luo D
    Sci Rep; 2022 Dec; 12(1):22299. PubMed ID: 36566332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sacral Neuromodulation with the InterStim System for Overactive Bladder: 3-Year Results from the French Prospective, Multicenter, Observational SOUNDS Study.
    Chartier-Kastler E; Normand LL; Ruffion A; Saussine C; Braguet R; Rabut B; Ragni E; Perrouin-Verbe MA; Pierrevelcin J; Rousseau T; Gamé X; Tanneau Y; Dargent F; Biardeau X; Graziana JP; Stoica G; Brassart E; Fourmarier M; Yaghi N; Capon G; Ferchaud J; Berrogain N; Peyrat L; Pecoux F; Bryckaert PE; Melotti A; Abouihia A; Keller DUJ; Cornu JN
    Eur Urol Focus; 2022 Sep; 8(5):1399-1407. PubMed ID: 34334342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective, multicenter study of a novel, miniaturized rechargeable sacral neuromodulation system: 12-month results from the RELAX-OAB study.
    Blok B; Van Kerrebroeck P; de Wachter S; Ruffion A; Van der Aa F; Jairam R; Perrouin-Verbe MA; Elneil S
    Neurourol Urodyn; 2019 Feb; 38(2):689-695. PubMed ID: 30592526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Five-year Results from the Prospective, Multicenter, Observational SOUNDS Study of Patients with Overactive Bladder Treated with the InterStim System for Sacral Neuromodulation.
    Chartier-Kastler E; Le Normand L; Ruffion A; Saussine C; Braguet R; Rabut B; Ragni E; Perrouin-Verbe MA; Pierrevelcin J; Rousseau T; Gamé X; Tanneau Y; Dargent F; Biardeau X; Graziana JP; Stoica G; Brassart E; Fourmarier M; Yaghi N; Capon G; Ferchaud J; Berrogain N; Peyrat L; Pecoux F; Bryckaert PE; Karsenty G; Song S; Keller DUJ; Cornu JN
    Eur Urol Focus; 2023 Sep; 9(5):765-772. PubMed ID: 37019729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Five-Year Followup Results of a Prospective, Multicenter Study of Patients with Overactive Bladder Treated with Sacral Neuromodulation.
    Siegel S; Noblett K; Mangel J; Bennett J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Zylstra S; Kan F; Berg KC
    J Urol; 2018 Jan; 199(1):229-236. PubMed ID: 28709886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baseline symptom severity and therapeutic success in a large prospective trial of sacral neuromodulation therapy for overactive bladder patients.
    Noblett K; Berg KC; Kan F; Siegel S
    Neurourol Urodyn; 2018 Jun; 37(5):1667-1671. PubMed ID: 29635879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variable frequency stimulation of sacral neuromodulation in black-zone overactive bladder patients: a case report.
    Meng L; Diao T; Wang M; Liu X; Zhang W; Tian Z; Wang J; Zhang Y
    Transl Androl Urol; 2020 Dec; 9(6):2842-2847. PubMed ID: 33457256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two-year safety and efficacy outcomes for the treatment of overactive bladder using a long-lived rechargeable sacral neuromodulation system.
    Blok B; Van Kerrebroeck P; de Wachter S; Ruffion A; Van der Aa F; Perrouin-Verbe MA; Elneil S
    Neurourol Urodyn; 2020 Apr; 39(4):1108-1114. PubMed ID: 32243625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does urinary urgency drive urinary frequency in overactive bladder?
    Versi E; Rovner ES; Dmochowski RR; Tu LM; De Wachter S
    Low Urin Tract Symptoms; 2022 Jul; 14(4):242-247. PubMed ID: 35233968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative study between sacral neuromodulation and intravesical botulinum toxin injection for patients with refractory overactive bladder.
    Al-Azzawi IS; Al-Hindawi HT
    Arab J Urol; 2020 Mar; 18(2):88-93. PubMed ID: 33029412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.
    Chapple C; Schneider T; Haab F; Sun F; Whelan L; Scholfield D; Dragon E; Mangan E
    BJU Int; 2014 Sep; 114(3):418-26. PubMed ID: 24552358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Prospective Study to Evaluate Efficacy Using the Nuro Percutaneous Tibial Neuromodulation System in Drug-Naïve Patients With Overactive Bladder Syndrome.
    Kobashi K; Nitti V; Margolis E; Sand P; Siegel S; Khandwala S; Newman D; MacDiarmid SA; Kan F; Michaud E
    Urology; 2019 Sep; 131():77-82. PubMed ID: 31199966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.